NEXICLON XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEXICLON XR (NEXICLON XR).
NEXICLON XR is a centrally acting alpha-2 adrenergic agonist that stimulates alpha-2 adrenergic receptors in the brainstem, reducing sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance and reduced blood pressure. The extended-release formulation provides sustained drug release.
| Metabolism | Metabolized primarily by the liver via CYP2D6; also undergoes glucuronidation. Approximately 50% of the dose is metabolized to inactive metabolites, and 46% is excreted unchanged in urine. |
| Excretion | Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites. |
| Half-life | Terminal elimination half-life: 12–15 hours; clinical context: once-daily dosing maintains therapeutic levels. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.5–0.7 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: 85% (immediate-release); extended-release: 90% relative to IR. |
| Onset of Action | Oral: 1–2 hours to therapeutic effect. |
| Duration of Action | Duration: 24 hours; clinical note: once-daily dosing provides consistent control. |
NEXICLON XR (clonidine extended-release) is administered orally. Typical adult dose for hypertension: 0.1 mg to 0.2 mg once daily at bedtime. May be titrated up to 0.6 mg/day. For ADHD: initial 0.1 mg once daily, adjusted weekly by 0.1 mg/day; maximum 0.4 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For GFR 30-60 mL/min: start at 0.1 mg once daily, titrate cautiously. GFR <30 mL/min: start at 0.1 mg once daily, maximum 0.3 mg/day. Hemodialysis: avoid or use with extreme caution; dose after dialysis if needed. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: initial 0.1 mg once daily, titrate slowly. Child-Pugh C: not recommended due to risk of accumulation. |
| Pediatric use | For ADHD in children ≥6 years: starting dose 0.1 mg orally once daily at bedtime. Titrate weekly by 0.1 mg/day; maximum 0.4 mg/day. Weight-based: not typically used; fixed dosing per age weight bands not established. Safety and efficacy for hypertension in children not established. |
| Geriatric use | Elderly patients: initiate at 0.1 mg once daily at bedtime. Titrate slowly due to increased sensitivity to hypotension, sedation, and bradycardia. Maximum 0.3 mg/day. Monitor renal function and electrolyte balance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEXICLON XR (NEXICLON XR).
| Breastfeeding | Excreted in breast milk with an M/P ratio of approximately 0.8. Limited data; potential for infant toxicity (hypotension, bradycardia). Use contraindicated while breastfeeding. |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects, oral clefts, and cardiac malformations based on animal studies and limited human data (FDA Pregnancy Category C). Second/Third trimester: Potential for fetal growth restriction, preterm labor, and oligohydramnios due to maternal toxicity. Avoid use unless benefit outweighs risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to clonidine or any component of the formulation"]
| Precautions | ["Rebound hypertension upon abrupt discontinuation (monitor blood pressure closely and taper slowly over several days)","Sedation and dizziness (caution when driving or operating machinery)","Concomitant use with CNS depressants may enhance sedation","Use in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure requires caution","Hepatic impairment may require dose adjustment"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, liver function tests, renal function, and electrocardiogram regularly. Fetal monitoring: serial ultrasounds for growth assessment and amniotic fluid index; consider fetal echocardiogram due to cardiac risks. |
| Fertility Effects | May impair fertility in both males (spermatogenic disruption) and females (ovarian suppression with anovulation). Reversible upon discontinuation. |